Bringing the Oncology Community Together

Bone Metastases

Latest Bone Metastases Articles View more >>
Radium-223 Approved For Advanced Prostate Cancer
Radium-223 Approved For Advanced Prostate Cancer
The FDA approved radium RA 223 dichloride for the treatment of symptomatic metastatic castration-resistant prostate cancer that has spread to the bones but not to any other organs.
Bone-Targeted Therapies Evolve in Prostate Cancer
Bone-Targeted Therapies Evolve in Prostate Cancer
The treatment of bone metastases in prostate cancer has changed over the years, and several options are now either available or under development.
Trials in Progress: Bone Metastases
Trials in Progress: Bone Metastases
The Trials in Progress series is intended to stimulate discussion about ongoing clinical trials, to promote collaboration across the oncology community.
Microwave Ablation Is Potentially Effective in Treating Bone and Soft-Tissue Tumor Pain
Microwave Ablation Is Potentially Effective in Treating Bone and Soft-Tissue Tumor Pain
A small study found that microwave ablation therapy reduced pain associated with bone and soft tissues by half in the majority of patients treated with the technique.
FDA Gives Radium-223 Priority Review Status
FDA Gives Radium-223 Priority Review Status
Radium Ra 223 Dichloride will be considered as a treatment for patients who have castration-resistant prostate cancer with bone metastases under the FDA’s priority review program.
The Educated Patient
The Educated Patient Bone Metastases Resource Guide

Bone Metastases
Resource Guide

Publications
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.